BCL2 and myelodysplastic syndrome: In contrast with our AML model where the RAS:BCL-2 complex localizes in the mitochondria where the cells have reduced apoptosis, after ABT-737 treatment, the complex is found in the plasma membrane with an increase in MMP [9], in the HR-MDS model, there was no change in MMP between diseased cells and cells from wild type healthy animals and between pre and post-treatment with the RAS:BCL-2 complex remaining in the plasma membrane.